Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05329779 · ClinicalTrials.gov registry record · Phase 4
Study on Allopregnanolone and Depression in Perimenopausal Women
A Phase 4 study, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT05329779 is a Phase 4 study that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 2 participants.
The verdict
NCT05329779, a Phase 4 study, was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study aims to identify how the progesterone metabolite allopregnanolone affects behavior and neurobiology that may underlie perimenopausal depression.
Interventions
- DRUG placebo
- DRUG brexanolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2022-11-04 |
| Est. Completion | 2023-07-18 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05329779
The ClinicalTrials.gov registry entry for NCT05329779 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT05329779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05329779 about?
NCT05329779 is a clinical study titled "Study on Allopregnanolone and Depression in Perimenopausal Women". This study aims to identify how the progesterone metabolite allopregnanolone affects behavior and neurobiology that may underlie perimenopausal depression.
What is the current status of trial NCT05329779?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2022-11-04. Estimated completion is 2023-07-18.
What interventions are being tested in trial NCT05329779?
The interventions under investigation include: placebo (DRUG), brexanolone (DRUG).
Who is sponsoring clinical trial NCT05329779?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.